{
    "clinical_study": {
        "@rank": "63769", 
        "arm_group": {
            "arm_group_label": "Single arm", 
            "description": "Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery."
        }, 
        "biospec_descr": {
            "textblock": "This study includes the collection of fresh-frozen tumor biopsies at the time of breast\n      cancer surgery."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "In this prospective study the investigators sought to evaluate the feasibility of using the\n      genomic signature - Genomic Grade Index (GGI) - in routine clinical practice and its impact\n      on treatment recommendations."
        }, 
        "brief_title": "Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer", 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": "Invasive Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study was to evaluate the feasibility of implementing Genomic\n      Grade Index (GGI) in community hospitals in Belgium for breast cancer patients with node\n      negative and 1-3 node positive early breast cancer. GGI would be considered a feasible\n      genomic test if results were obtained in > 70% of evaluated patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Histologically confirmed invasive breast cancer meeting the following criteria:\n\n          -  T1, T2, or operable T3 disease\n\n          -  Zero to three positive lymph nodes and no distant metastases\n\n          -  Operable disease - Must have undergone breast-conserving surgery or mastectomy with\n             either a sentinel node procedure or full axillary clearance\n\n        Exclusion Criteria:\n\n          -  No other invasive cancer within the past 5 years except for adequately treated\n             carcinoma in situ of the cervix or non melanoma skin cancer\n\n          -  No psychological, familial, sociological, or geographical condition that would\n             preclude entering into a clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This study includes patients diagnosed with early-stage invasive breast cancer and\n        operable disease."
            }
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916837", 
            "org_study_id": "1668", 
            "secondary_id": "2009-015521-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "Single arm", 
                "description": "Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery", 
                "intervention_name": "Sampling of tumor tissue", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Single arm", 
                "description": "Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery", 
                "intervention_name": "Sampling of tumor tissue after breast cancer surgery", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Single arm", 
                "description": "Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery", 
                "intervention_name": "Sampling of tumor tissue after breast cancer surgery", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast cancer", 
            "Feasibility", 
            "Genomic grade index"
        ], 
        "lastchanged_date": "August 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "1000"
                }, 
                "name": "Institut Jules Bordet"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer", 
        "other_outcome": {
            "description": "To test the success rate of reporting GGI, a minimum sample size of 137 was calculated to have a power of 90% at a one-sided significance level of 5% using an empirical estimate of variance (null hypothesis H0: p \u2264 0.70 vs. alternative hypothesis HA: p \u2265 0.80).", 
            "measure": "The success rate of reporting Genomic Grade Index results", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the feasibility of implementing Genomic Grade Index in community hospitals in Belgium for breast cancer patients diagnosed with node negative and 1-3 node positive early-stage invasive breast cancer", 
            "measure": "The success rate in obtaining the Genomic Grade Index in clinical practice", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916837"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary objective was to evaluate the impact of Genomic Grade Index on adjuvant treatment decisions for patients with early breast cancer.  This was done by comparing physicians' treatment recommendations before having knowledge of the GGI test results to recommendations with a hypothetical GG-1 and GG-3 result and to the treatment ultimately administered after discussion with the patient.", 
            "measure": "The impact of Genomic Grade Index results on adjuvant treatment decision", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Jules Bordet Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jules Bordet Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2010", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}